COLLEGIUM PHARMACEUTICAL, INC (COLL) — Current Report

AI-Powered SEC Filing Analysis

Latest Current Report Filed: 2026-05-15

Key Insights

All eight director nominees were successfully elected with substantial shareholder support, with Michael Donovan receiving the highest vote count (27.38M for votes, 99.87% approval rate), indicating strong board confidence.
Executive compensation received advisory shareholder approval with 96.0% voting in favor (26.31M for votes), demonstrating shareholder alignment with management's pay practices despite 1.10M opposing votes.
Deloitte & Touche LLP was ratified as the independent auditor with overwhelming approval at 99.1% (28.95M for votes) and zero broker non-votes, reflecting consistent audit firm confidence.
Voting participation was strong at 90.1% of shares outstanding (29.21M of 32.41M shares), suggesting healthy shareholder engagement in corporate governance matters.

Want the newest filings?

This analysis covers the filing from 2026-05-15. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Earlier Current Report filings

Filed: 2026-05-12

Collegium completed a major $650 million acquisition of AZSTARYS (a CNS stimulant for ADHD treatment) funded by $350 million cash and $300 million from delayed draw term loan, with up to $135 million in additional milestone-based payments.
Leadership departures of Chief Commercial Officer Scott Dreyer (effective August 30, 2026) and Chief Medical Officer Thomas Smith signal potential integration challenges or strategic repositioning following the significant acquisition.
The company adopted a 2026 Inducement Plan for 325,000 shares to attract new employees, likely reflecting staffing needs to integrate the acquired AZSTARYS business and support commercial expansion.
Financial statements and pro forma information for the acquisition will be filed within 71 days, leaving investors awaiting detailed analysis of the acquisition's financial impact and integration plans.

Filed: 2026-05-07

Collegium Pharmaceutical announced Q1 2026 financial results on May 7, 2026, with earnings presentation accompanying the earnings release, indicating normal quarterly reporting cycle.
The filing is a routine 8-K for earnings disclosure under Item 2.02 and includes supplemental presentation materials under Item 7.01 Regulation FD Disclosure, typical for pharmaceutical company quarterly updates.
Signed by CFO Colleen Tupper, confirming proper corporate authorization and that financial results have been prepared and disclosed in accordance with SEC requirements.
No material events, significant guidance changes, strategic transactions, or leadership changes are indicated in this filing - it appears to be a standard quarterly earnings announcement.

Filed: 2026-04-07

Collegium Pharmaceutical nominated Michael Donovan, a former EY audit partner with extensive life sciences industry experience, to stand for election to the board at the 2026 Annual Meeting.
John Fallon, a current board member since 2016, will not stand for re-election and will retire from the board at the 2026 Annual Meeting.
The board refreshment and succession planning does not appear to be due to any disagreement with the company, signaling an orderly transition.

Filed: 2026-02-26

Collegium Pharmaceutical reported its Q4 and full-year 2025 financial results, indicating the company's performance during this period.
The earnings presentation provides additional details on the company's financial and operational performance, which investors may find useful.
There are no other material disclosures or events reported in this 8-K filing beyond the earnings announcement and presentation.

Filed: 2026-01-08

Collegium Pharmaceutical provided full-year 2026 revenue and adjusted EBITDA guidance, indicating the company's financial outlook for the year.
The company posted a new corporate presentation that representatives may use in discussions with investors, analysts, and other parties, potentially providing insights into the company's strategy and performance.
The filing highlights several risk factors that could impact the company's future performance, including regulatory, commercial, and financial risks.

Filed: 2025-12-30

Collegium Pharmaceutical has entered into a new $980 million credit agreement, including a $580 million term loan, $300 million in delayed draw term loan commitments, and a $100 million revolving credit facility.
The new credit agreement will be used to repay the company's existing credit facility, pay fees and expenses, and provide funding for general corporate purposes.
The new credit agreement includes customary financial covenants, such as a first lien secured net leverage ratio and fixed charge coverage ratio, as well as provisions for scheduled quarterly repayments and optional prepayments without penalty.

Other reports for COLLEGIUM PHARMACEUTICAL, INC

Insider Trading Quarterly Report Annual Report

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.